Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy
Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy作者机构:Gastroenterology UnitDepartment of Internal MedicineUniversity Tor Vergata Department of Experimental Medicine and SurgeryUniversity Tor Vergata
出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))
年 卷 期:2015年第21卷第21期
页 面:6698-6705页
核心收录:
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题:Doxycycline Eradication therapy Urea breath test Esomeprazole Levofloxacin Helicobacter pylori
摘 要:AIM:To evaluate a levofloxacin-doxycycline-based triple therapy with or without a susceptibility culture test in non-responders to Helicobacter pylori(***) ***:A total of 142(99 women,43 men; mean 53.0 ± 12.7 years) non-responders to more than two *** eradication therapies underwent susceptibility culture tests or were treated with a seven-day triple therapy consisting of esomeprazole,20 mg b.i.d.,levofloxacin,500 mg b.i.d.,and doxycycline,100 mg b.i.d.,randomly associated with(n = 71) or without(n = 71) Lactobacillus casei *** status was checked in all patients at enrollment and at least 8 wk after the end of *** and tolerability of regimens were also ***:*** eradication was achieved in 50% of patients [per prototol(PP) = 49%; intention to treat(ITT) = 46%].Eradication rate was higher in patients administered probiotics than in those without(PP = 55% vs 43%; ITT = 54% vs 40%).Estimated primary resistance to levofloxacin was 18% and multiple resistance was 31%.Therapy was well tolerated,and side effects were generally mild,with only one patient experiencing severe ***:Third-line levofloxacin-doxycycline triple therapy had a low *** eradication efficacy,though the success and tolerability of this treatment may be enhanced with probiotics.